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Abstract
Hepatocellular carcinoma is a major cause of cancer-related
deaths. Current treatments are not effective, and the
identification of relevant pathways and novel therapeutic
targets are much needed. Increasing evidences point to the
activation of the epidermal growth factor receptor (EGFR) as
an important mechanism in the development of hepatocarci-
noma. We previously described that amphiregulin (AR), a
ligand of the EGFR, is not expressed in healthy liver but is up-
regulated during chronic liver injury, the background on
which most liver tumors develop. Now, we have studied the
expression and role of AR in human hepatocarcinoma. AR
expression and function was studied in human liver tumors
and cell lines. AR is expressed in human hepatocellular
carcinoma tissues and cell lines and behaves as a mitogenic
and antiapoptotic growth factor for hepatocarcinoma cells.
We provide several lines of evidence, including AR silencing by
small interfering RNAs and inhibition of amphiregulin by
neutralizing antibodies, showing the existence of an AR-
mediated autocrine loop that contributes to the transformed
phenotype. Indeed, interference with endogenous AR produc-
tion resulted in reduced constitutive EGFR signaling, inhibi-
tion of cell proliferation, anchorage-independent growth, and
enhanced apoptosis. Moreover, knockdown of AR potentiated
transforming growth factor-B and doxorubicin-induced apo-
ptosis. Conversely, overexpression of AR in SK-Hep1 cells
enhanced their proliferation rate, anchorage-independent
growth, drug resistance, and in vivo tumorigenic potential.
These observations suggest that AR is involved in the
acquisition of neoplastic traits in the liver and thus constitutes
a novel therapeutic target in human hepatocarcinoma. (Cancer
Res 2006; 66(12): 6129-38)
Introduction
Hepatocellular carcinoma is a malignancy of worldwide
significance, being the fifth most common solid tumor and a
leading cause of cancer-related death (1). Its incidence is high in
developing countries and is continuously rising in western society,
mainly due to the dissemination of hepatitis C virus infection,
excessive alcohol intake, and the increase in nonalcoholic fatty liver
disease-associated cirrhosis, major risk factors for hepatocellular
carcinoma (1). Most hepatocellular carcinoma patients are
diagnosed at advanced stages, when they are not suitable for
curative therapies, such as resection and transplantation (1), and
currently available chemotherapeutic options are not effective,
with poor responses and low survival of patients with advanced
hepatocellular carcinoma (1).
Hepatocellular carcinoma is strongly associated with chronic
liver diseases, including chronic hepatitis and cirrhosis, which are
regarded as preneoplastic conditions for this malignancy (2, 3). The
genomic alterations leading to the development of the neoplastic
phenotype of the hepatocyte seem to be heterogeneous, and
diverse combinations of these aberrations may result in the
malignization of the liver parenchymal cell (1–4). However, a
common feature found in the preneoplastic liver is the increase in
the proliferation of both regenerative and dysplastic hepatocytes
compared with non-diseased liver (3). This enhanced cellular
proliferation, accompanied by reduced rates of cell death, is
thought to be essential for the development of the full neoplastic
phenotype, facilitating the accumulation of genetic alterations in a
large population of progeny cells (2, 3). One of the major molecular
mechanisms that drive the hyperproliferative condition found in
chronically injured liver is the elevated expression of mitogenic
factors for the hepatocytes. Initially, this response can be part of
the endogenous regenerative and defense mechanisms of the
injured liver to the loss of parenchymal cells (5). However, its
perpetuation is thought to participate in the multistep process of
hepatocarcinogenesis through the establishment of autocrine
mechanisms for self-sustaining cellular growth (2–4). The epider-
mal growth factor receptor (EGFR), a transmembrane tyrosine
kinase, is highly expressed in normal and transformed hepatocytes
and is believed to convey essential mitogenic and survival signals
in transformed cells, including hepatocellular carcinoma cells (2, 3,
6, 7). In support of this notion are recent reports that describe the
prevention of chemically induced hepatocellular carcinoma in rats
and the growth of human hepatocellular carcinoma cell lines by
gefitinib, an inhibitor of EGFR tyrosine kinase activity (8–10). The
EGFR can be bound and activated by a broad family of ligands, that
besides EGF include transforming growth factor-a (TGF-a),
heparin-binding EGF-like growth factor (HB-EGF), betacellulin,
epiregulin, and amphiregulin (AR; refs. 11–13). Overexpression of
TGF-a and HB-EGF has been observed in liver cirrhosis and
hepatocellular carcinoma, and these factors are believed to
contribute to EGFR activation during hepatocarcinogenesis
(14, 15). We have recently reported that AR, a heparin-binding
EGFR ligand with undetectable expression in normal liver, is
readily induced in the regenerating liver after partial hepatectomy
and behaves as a potent mitogenic and antiapoptotic factor for
normal hepatocytes (16, 17). The role played by AR in hepatocyte
proliferation and cytoprotection seems to be unique because
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studies in AR knockout mice showed that the effects exerted by AR
on liver parenchymal cells could not be compensated by other
EGFR ligands, such as TGF-a and HB-EGF, also induced during
liver injury (16–19). We have also observed that AR gene expression
was up-regulated in the premalignant cirrhotic human liver and in
experimental liver cirrhosis in rats (16). Together, these findings led
us to speculate that AR might have a role in hepatocarcinogenesis,
and thus that an AR-mediated autocrine or paracrine loop could
contribute to the growth of hepatocellular carcinoma cells. Our
present results support the notion that AR can be considered as
one key activator of the EGFR signaling pathway in the
unrestrained growth and apoptosis resistance of hepatocellular
carcinoma cells.
Materials and Methods
Materials. Cell culture media, serum, glutamine, and antibiotics were
from Life Technologies/Invitrogen (Barcelona, Spain). Human recombinant
AR, forskolin, doxorubicin, goat serum IgG, and heparin were from Sigma
(St. Louis, MO). TGF-h was from Roche (Penzberg, Germany). The
metalloproteinase inhibitor GM6001 and the EGFR inhibitor PD153035
were from Calbiochem (San Diego, CA). Antibodies used were anti-human
AR goat polyclonal antibody (AF262) from R&D Systems (Minneapolis, MN);
phosphorylated Akt (Ser473; 9271S), c-Jun NH2-terminal kinase (JNK; 9252),
phosphorylated JNK (Thr183/Tyr185; 9251), and active caspase-3 p17 subunit
(9664S) from Cell Signaling (Beverly, MA); extracellular signal-regulated
kinase (Erk1/2; 06-182) and phosphorylated EGFR (Tyr1148; 4404) from
Upstate Biotechnology (Charlottesville, VA); phosphorylated Erk1/2 (Tyr204;
sc7383), EGFR (sc03), Akt (sc5298), and h-actin from Santa Cruz
Biotechnology (Santa Cruz, CA); and anti-Bim antibody (AB17003) from
Chemicon (Temecula, CA).
Patients. Liver tissue was obtained from three groups of subjects: (a)
Control individuals (n = 11; all males; mean age, 58 years; range, 45-70 years)
with normal or minimal changes in the liver. Tissue samples were collected at
surgery of digestive tumors of from percutaneous liver biopsy done because
of mild alteration of liver function tests. (b) Patients with liver cirrhosis of
different etiology (n = 14; 9 males; mean age, 60 years; range, 42-77 years):
9 patients with hepatitis C viral cirrhosis, 3 patients with hepatitis B viral
cirrhosis, and 2 patients with alcoholic cirrhosis. (c) Patients with primary
hepatocellular carcinoma (n = 19; all males; mean age, 67 years; range, 39-79
years). Cancerous liver tissues were obtained during surgical resection. This
study was approved by the University of Navarra Human Research Review
Committee.
Cell culture and treatments. The human hepatocellular carcinoma cell
lines HepG2, Hep3B, HuH7, PLC/PRF/5, and SK-Hep1 and the human non–
small cell lung cancer cell lines H322 and H358 were grown in DMEM
supplemented with 10% fetal bovine serum, glutamine, and antibiotics.
Where indicated, serum was removed from the culture medium. Anchorage-
independent growth of human hepatocellular carcinoma cells was assessed
by colony formation ability in soft agar and was done as previously
described (20). After 4 weeks, colonies were counted. Data are means of
three independent experiments done in duplicates.
RNA isolation and analysis of gene expression. Total RNA was
extracted using the TRI Reagent (Sigma). Reverse transcription and real-
time PCR was done using an iCycler (Bio-Rad, Hercules, CA) and the iQ
SYBR Green Supermix (Bio-Rad) as previously described (17). The amount
of each transcript was expressed as the n-fold difference relative to the
control gene b-actin (2DCt, where DC t represents the difference in threshold
cycle between the control and target genes), as previously described (21).
Multiplex reverse transcription-PCR (RT-PCR) was carried out as reported
(22). The primers used for AR, HB-EGF, and TGF-a determinations were the
same used in previous publications (16, 17). Primers used to assess TACE/
ADAM17 gene expression were as reported (23).
Western blot analysis and AR ELISA. Hepatocellular carcinoma cells
were lysed, and homogenates were subjected to Western blot analyses as
reported (16, 17). Soluble AR was measured in hepatocellular carcinoma
cells’ conditioned media (CM) by ELISA. For this purpose, cells were seeded
into six-well plates (1.5  105 per well) and incubated for 48 hours in culture
medium with or without serum. CM were collected and, after addition of
phenylmethylsulfonyl fluoride (1 mmol/L), was precleared by centrifugation
(15 minutes; 14,000 rpm) and lyophilized. The concentration of AR in CM
was determined by sandwich ELISA from R&D Systems, using a monoclonal
anti-AR capture antibody (MAB262) and a biotinylated polyclonal detection
antibody (BAF262). A standard curve using recombinant human AR was
used to calculate AR concentrations in CM.
Transfections. SK-Hep1 cells grown in 60-mm dishes until 70%
confluence were transfected with a pcDNA3 plasmid (Invitrogen, Carlsbad,
CA) harboring the complete murine AR cDNA previously described (24), or
the empty pcDNA3 vector. Transfections were carried out using calcium
phosphate, and transfectants were selected in complete medium containing
0.6 mg/mL of G418 sulfate (Geneticin; Invitrogen) as described (20). After
2 weeks, individual colonies were harvested, and clones transfected with
the empty vector pcDNA3 (SK-EV) or the AR expressing construct (SK-AR)
were expanded.
RNA interference. The sequences of the small interfering RNAs (siRNA)
targeting different regions of the human AR gene (siAR1 and siAR2) and the
control siRNA (siGL2) along with their specificity have been described (23).
These siRNAs were obtained from Dharmacon Research (Lafayette, CO).
Transfections of the 21-nucleotide siRNA duplexes (100 nmol/L) were
carried out using the Dharmafect reagent (Dharmacon Research) following
the manufacturer’s instructions. Silencing of AR was confirmed by RT-PCR
and by quantitating the amount of AR in CM.
Cell growth and apoptosis assays. Cell proliferation and viability was
estimated using the cell proliferation reagent WST-1 from Roche. Apoptosis
was estimated by the determination of soluble histone-DNA complexes using
the Cell Death Detection Assay (Roche). Specific enrichment of mono-
nucleosomes and oligonucleosomes released into the cytoplasm (enrichment
factor) was calculated as the ratio between the absorbance values of the
samples obtained from treated and control cells as previously described (17).
Tumor growth in nude mice. Five million cells were inoculated s.c. in
the dorsal flanks of 4-week-old male BALB/c athymic nude mice (Harlan,
Barcelona, Spain).
Statistical analysis. Normally distributed data were compared among
groups using the Student’s t test. Non-normally distributed data were
compared using the Mann-Whitney test. Data are means F SE. P < 0.05 was
considered significant.
Results
Expression of AR is up-regulated in human hepatocellular
carcinoma tissue and hepatocellular carcinoma cell lines. We
have previously reported that AR gene expression is up-regulated in
human and experimental liver cirrhosis (16). It has been proposed
that persistent activation of growth and survival pathways during
liver cirrhosis may contribute to the pathogenesis of hepatocellular
carcinoma (2, 3, 6). These notions led us now to evaluate whether
the expression of AR was also elevated in the neoplastic liver. As
shown in Fig. 1A , whereas real-time PCR analysis of control
samples showed barely detectable levels of AR mRNA, AR
expression was significantly increased in about 70% of hepatocel-
lular carcinoma tissue samples (13 of 19). All EGFR ligands,
including AR, are synthesized as membrane-anchored precursors
that can be proteolytically released from the cell surface, allowing
their autocrine and paracrine interactions with the EGFR (25). This
shedding is carried out by a family of membrane-anchored
metalloproteases known as ‘‘a disintegrin and metalloprotease’’
(ADAM) proteins (26). The shedding of AR from the cell membrane
is carried out by ADAM17, also known as tumor necrosis factor-a
converting enzyme (TACE; ref. 24). We have measured the
expression of ADAM17 in samples from human hepatocellular
carcinoma tissue by real-time PCR (Fig. 1B) and found it to be
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significantly higher than in controls. Interestingly, we observed that
the mRNA levels of ADAM17 were already significantly elevated in
cirrhotic liver tissue compared with healthy controls, and that
there were no differences between cirrhotic liver and hepatocellular
carcinoma samples in terms of ADAM17 gene expression. There
was no association between ADAM17 gene expression levels and
the etiology of cirrhosis.
Next, we tested the expression of AR in five human hepatocel-
lular carcinoma cell lines by real-time PCR. AR was found to be
expressed, albeit to different extent, in all but one of the human
hepatocellular carcinoma cell lines examined (Fig. 1C). Shedding of
AR is essential for autocrine and paracrine signaling through the
EGFR (26). To establish whether such autocrine system could occur
in hepatocellular carcinoma, it was important to ascertain if
hepatocellular carcinoma cells not only expressed but also released
AR to the culture medium. We did an ELISA assay for AR using the
human lung cancer cell lines H322 and H358 as controls for AR
producing and nonproducing cells, respectively (27), and we were
able to detect AR protein accumulation in the CM of the two
hepatocellular carcinoma cell lines tested (PLC and Hep3B; Fig.
1D). Interestingly, we observed that when cells were cultured in the
absence of serum, AR production was enhanced (Fig. 1D).
AR treatment of hepatocellular carcinoma cells stimulates
cell growth and confers apoptosis resistance. We have
previously shown that AR is a mitogenic factor for normal rodent
hepatocytes in primary culture (16). However, AR was originally
described as a bifunctional protein not only capable of stimulating
the growth of normal epithelial cells but also able to inhibit that of
certain carcinoma cell lines (28); therefore, it was critical to
establish the effect of AR on hepatocellular carcinoma cells. We
observed that treatment of Hep3B and PLC cells with AR in the
absence of serum increased the growth of these cells in a dose-
dependent manner, and that this effect was blocked by the EGFR-
specific inhibitor PD153035 (Fig. 2A). Similar results were obtained
using HuH7 (data not shown). Interestingly, in the presence of
PD153035, cell growth was reduced below levels found in serum-
starved cells, in agreement with the crucial role played by EGFR-
conveyed growth signals for hepatocellular carcinoma cells (8–10).
Besides providing growth-promoting signals, activation of the
EGFR enhances survival of hepatocytes and hepatocellular
carcinoma cells (9, 17). In agreement with this, we observed that
AR efficiently prevented TGF-h-induced apoptosis in Hep3B cells
(Fig. 2B). Consistent with the observed biological effects of AR,
treatment of Hep3B cells with AR resulted in the rapid
Figure 1. A, AR gene expression in human hepatocellular carcinoma tissues. B, ADAM17 /TACE gene expression in human liver cirrhosis and hepatocellular
carcinoma tissues. C, AR gene expression in human hepatocellular carcinoma cell lines. Gene expression was measured by real-time PCR. D, AR protein contents
in CM obtained from Hep3B and PLC human hepatocellular carcinoma cell lines grown in the presence (+FCS ) or absence (FCS ) of 10% FCS for 48 hours. CM from
the human non–small cell lung carcinoma cell lines H358 and H322 were used as positive and negative controls for AR production, respectively. AR in CM was
measured by ELISA. Points /columns, means of three independent experiments done in duplicates; bars, SE. *, P < 0.05.
Amphiregulin Autocrine Loop in Hepatocarcinoma
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phosphorylation of the EGFR and the downstream effector kinases
Erk1/2 and Akt in an EGFR-dependent manner, as indicated by the
inhibitory effect of PD153035 (Fig. 2C). In agreement with previous
observations, the potent activation of Erk2 phosphorylation
elicited by AR treatment was accompanied by a shift in mobility
of the phosphorylated protein. Similar results were obtained with
PLC and HuH7 cells (data not shown).
In human colon carcinoma cells, AR gene expression is
promoted by cyclooxygenase-2-generated prostaglandin E2,
through the stimulation of protein kinase A (PKA), in conjunction
with the activation of the EGFR by TGF-a (29). In agreement with
this, and our previous observations in primary hepatocytes (16), we
observed that the PKA activator forskolin induced AR gene
expression in Hep3B cells (data not shown), and that AR itself
could promote its own expression through the activation of the
EGFR (Fig. 1D).
Characterization and functional relevance of an AR-medi-
ated autocrine loop in hepatocellular carcinoma cells. We also
examined the effects of self-produced AR on hepatocellular
carcinoma cells. To this end, we interfered with AR autocrine
signaling at different levels in serum-free cultures of hepatocel-
lular carcinoma cells. First, we showed that Hep3B and PLC cell
growth was attenuated by an AR-neutralizing antibody (Fig. 3A).
As previously mentioned, AR is synthesized as a membrane-
anchored precursor that is released by the action of the
metalloprotease ADAM17 (25, 26). We observed that addition of
the metalloprotease inhibitor GM6001 reduced the serum-
independent growth of Hep3B and PLC cells (Fig. 3A). Similar
to HB-EGF, AR contains a heparin-binding domain, and it has
been reported that addition of heparin inhibits AR-mediated
autocrine growth of human keratinocytes (30). When Hep3B and
PLC cells were cultured in serum-free medium, we observed that
the presence of heparin significantly inhibited the proliferation of
these hepatocellular carcinoma cell lines (Fig. 3A). The effect of
these two pharmacologic interventions on the autocrine growth
of hepatocellular carcinoma cells was mimicked by PD153035 and
was accompanied by a significant attenuation of the enhanced
basal levels of Erk1/2 phosphorylation found in hepatocellular
carcinoma cells (ref. 31; Fig. 3B). We did an additional experiment
in which CM obtained from PLC cells was added to serum-
depleted cultures of HuH7 cells, and cellular proliferation was
subsequently measured. We observed that CM obtained from PLC
cells contained a growth-promoting activity for HuH7 cells, and
that this proliferative response was completely blunted by the
Figure 2. A, AR treatment induces cell growth in Hep3B and PLC cells. Hep3B and PLC cells were treated with increasing concentrations of AR for 24 hours,
and growth was measured as described in Materials and Methods. Where indicated, cells were treated with the EGFR inhibitor PD153035 (1 Amol/L). Growth of cells in
the absence of serum was given the arbitrary value of 100%. Cell growth in the presence of 10% FCS is shown as control. *, P < 0.05 versus cells maintained in
0% FCS. #, P < 0.05 versus cells treated with 50 nmol/L AR. B, AR protects Hep3B cells from TGF-h-induced apoptosis. Apoptosis was induced by TGF-h (1 nmol/L)
treatment for 24 hours. Where indicated, cells were pretreated with AR (50 nmol/L) for 2 hours. Apoptosis was estimated by specific enrichment of mononucleosomes
and oligonucleosomes released into the cytoplasm as described in Materials and Methods. *, P < 0.05 versus TGF-h alone. C, AR treatment activates the EGFR
and EGFR-dependent downstream signaling (Erk1/2 and Akt) in Hep3B cells. Cells were treated with AR (20 nmol/L) for 10 minutes. Where indicated, cells were
pretreated with the EGFR inhibitor PD153035 (1 Amol/L) for 30 minutes. Representative Western blots. D, AR (20 nmol/L) stimulates its own gene expression in
Hep3B cells through the activation of the EGFR. PD153035 was added 30 minutes before AR, and treatment was continued for 6 hours. AR mRNA levels were
measured by real-time PCR. *, P < 0.05 versus AR alone. Points /columns, means of three independent experiments done in duplicates; bars, SE.
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EGFR inhibitor PD153035, or significantly attenuated by an AR-
neutralizing antibody (Fig. 3C). Consistent with these observa-
tions, treatment of HuH7 cells with PLC cells CM activated the
EGFR and EGFR-dependent downstream signaling (Erk1/2 and
Akt phosphorylation), responses that were specifically blunted by
an AR neutralizing antibody (Fig. 3D).
More compelling evidence on the importance of AR in maintain-
ing the hepatocellular carcinoma malignant phenotype was
obtained through two complementary strategies. First, the endog-
enous expression of AR was silenced by siRNAs oligos in the AR-
overexpressing PLC and Hep3B cells. Cell lysates and CM were
harvested at different time points after transfection and analyzed by
RT-PCR and ELISA, respectively. We confirmed the knockdown of
AR gene expression at the mRNA level and the reduced accumu-
lation of AR protein in CM from PLC cells (Fig. 4A) and Hep3B cells
(data not shown). The specific silencing of the AR gene expression
was further confirmed by the lack of effect of AR siRNAs on the
mRNA levels of the other EGFR ligands HB-EGF and TGF-a, which
are constitutively expressed in both PLC (Fig. 4A) and Hep3B cells
(data not shown). We next evaluated the functional consequences of
AR depletion in hepatocellular carcinoma cells. Blunted AR
production by AR siRNA transfection resulted in significantly
reduced basal EGFR activation, as determined by EGFR and Erk1/
2 phosphorylation levels, in PLC and Hep3B cells (Fig. 4B). We also
examined the proliferation and anchorage-independent growth of
hepatocellular carcinoma cells in which AR expression was down-
regulated. As shown in Fig. 4C , PLC and Hep3B siAR transfectants
presented significantly inhibited cell growth compared with control
cultures transfected with siGL2 (control siRNA). Interfering with
AR production also dramatically reduced the aggressiveness of
Figure 3. A, serum-free (0% FCS) growth of Hep3B and PLC cells in the presence of an AR-neutralizing antibody (aAR, 20 Ag/mL), the EGFR inhibitor PD153035
(1 Amol/L), heparin (40 Ag/L), or the ADAM17/TACE inhibitor GM6001 (40 Amol/L). *, P < 0.05 versus cells grown in 0% FCS. B, PD153035, heparin, and GM6001
down-regulate the basal levels of Erk1/2 phosphorylation. Hep3B cells were treated with the above-indicated concentrations of these compounds for 40 minutes,
and Erk1/2 phosphorylation levels were assessed by Western blotting. Representative blot. C, growth induced by PLC CM (PLC-CM) in HuH7 cells is AR dependent.
CM was obtained from PLC cells kept in serum-free conditions for 48 hours, and then it was added to subconfluent HuH7 cells. HuH7 cell growth was estimated
24 hours later as described in Materials and Methods. Where indicated, before treatment of HuH7, PLC-CM was incubated for 1 hour at 37jC with PD153035 (1 Amol/L),
AR-neutralizing antibody (aAR, 20 Ag/mL), or purified goat IgG (IgG, 20 Ag/mL). *, P < 0.05 versus HuH7 cells treated with PLC-CM alone. D, EGFR-dependent
signaling elicited by PLC-CM in HuH7 cells is inhibited by an AR-neutralizing antibody (aAR). HuH7 cells were treated for 10 minutes with PLC-CM; subsequently,
EGFR, Erk1/2, and Akt phosphorylation was estimated by Western blotting. Where indicated, before HuH7 treatment, PLC-CM was incubated with PD153035,
AR-neutralizing antibody, or purified goat IgG as described above. Representative blots.
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hepatocellular carcinoma cancer cells, as shown by the impaired
anchorage-independent growth in soft agar (Fig. 4D). Similar results
were also obtained in Hep3B cells (data not shown).
To further explore the influence of AR gene expression on the
behavior of hepatocellular carcinoma cells, we undertook a
complementary approach. It consisted in the transfection of SK-
Hep1 cells, the only human hepatocellular carcinoma cell line
tested that lacked AR gene expression, with a plasmid vector
harboring murine AR cDNA, and the generation of stable trans-
fected clones. As shown in Fig. 5A , transfected SK-Hep1 cells (SK-
AR1 and SK-AR2 clones) were confirmed to express AR mRNA and
to release AR to the CM. Next, we examined the growth properties
of SK-AR1 and SK-AR2 cells compared with the control SK-EV cells.
We observed that AR expressing cells exhibited enhanced growth
rate than SK-EV cells (Fig. 5B). Furthermore, the expression of AR
significantly enhanced the tumorigenic behavior of SK-Hep1 cells,
as assessed both in vitro and in vivo . The ability to form colonies in
soft agar and the tumorigenic potential of AR-expressing SK-Hep1
cells in athymic nude mice were significantly higher than those of
control cells that did not express AR (Fig. 5C and D).
AR expression contributes to the resistance of hepatocellu-
lar carcinoma cells to TGF-B and cytostatic drugs. Normal
hepatocytes do not express TGF-h and, when exposed to this
cytokine, undergo cell cycle arrest and apoptosis (5). In contrast,
hepatocellular carcinoma cells produce TGF-h and have lost the
sensitivity to TGF-h-induced apoptosis (2–4). This altered response
seems to be crucial for the establishment of a highly malignant and
invasive phenotype (32). To evaluate if the expression of AR in
hepatocellular carcinoma cells could contribute to TGF-h resis-
tance, we measured apoptosis in PLC cells after AR knockdown by
AR siRNA transfection. Consistent with our previous observations
using recombinant AR (Fig. 2B), we found that AR down-regulation
significantly increased the sensitivity of PLC cells towards TGF-
h-induced apoptosis (Fig. 6A). Interestingly, silencing of AR
resulted in enhanced basal apoptosis (Fig. 6A), which is in
agreement with the inability of PLC cells to survive in semisolid
medium when AR is down-regulated (Fig. 4D). The levels of the
active caspase-3 p17 subunit, shown in Fig. 6B , correlated well with
the extent of apoptosis induced by AR silencing and TGF-h
treatment (Fig. 6A). A common cellular response associated with
Figure 4. A, specific AR silencing by siRNAs in PLC cells. PLC cells were transfected with a mixture of two AR-specific siRNAs (50 nmol/L each; siAR), or a
control siRNA (100 nmol/L; siGL2). AR, HB-EGF, TGF-a, and actin gene expression was measured by RT-PCR 72 hours after transfections. Representative gels.
Bottom, relative AR protein levels in PLC CM 72 hours after transfection with siGL2 (given the arbitrary value of 100%) or siAR, as determined by ELISA. *, P < 0.05
versus siGL2. B, basal levels of EGFR and Erk1/2 phosphorylation in PLC and Hep3B cells 96 hours after transfection with either siGL2 or siAR as determined by
Western blotting. Representative blots. C, effect of AR silencing on the growth of PLC and Hep3B cells. Cell growth was measured at different time points after
transfections as described in Materials and Methods. *, P < 0.05 versus cells transfected with siGL2. D, effect of AR silencing on anchorage-independent cell
growth in soft agar. PLC cells were transfected with either siGL2 or siAR siRNAs. After 24 hours, cells were harvested, counted, resuspended in 0.2% soft agar,
and seeded onto 0.4% soft agar in DMEM supplemented with 10% FCS (104 per plate). After 4 weeks, colonies were stained with crystal violet and counted.
Points /columns, means of three experiments done in duplicates; bars, SE. Representative images.
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apoptosis induced by growth factor withdrawal and TGF-h
treatment is the activation of the expression of the BH3-only
protein Bim (33–35). Bim is a proapoptotic member of the Bcl-2
family that binds and neutralizes its prosurvival relatives, such as
Bcl-XL, priming the cell for apoptosis (33). We observed that upon
AR silencing and TGF-h treatment, Bim gene expression was up-
regulated at the mRNA (data not shown) and the protein level
(Fig. 6B). Bim expression is controlled at various levels through the
coordinate action of different signaling pathways (33). It is known
that sustained activation of EGFR and Erk signaling prevents Bim
up-regulation, whereas JNK activation triggers Bim expression and
activation (33, 36–38). Consistent with the reported mode of
regulation of Bim expression, we observed that concomitant with
the attenuation of Erk1/2 phosphorylation, JNK activity was
induced by AR down-regulation and TGF-h treatment (Fig. 6B).
The same results were obtained in Hep3B cells (data not shown).
Accumulating evidences underscore the relevance of EGFR
expression and activity for tumor cell drug resistance, including
human hepatocellular carcinoma cells (39). This fact, together with
our current observations on the promitogenic and antiapoptotic
properties of AR for hepatocellular carcinoma cells, prompted us to
evaluate whether AR expression could contribute to the resistance of
these cells to doxorubicin, one of the most commonly used
anticancer agents for solid tumors like hepatocellular carcinoma.
To this end, we examined the effect of doxorubicin on PLC cells
transfected with either control siRNA (siGL2) or with AR siRNAs
(siAR). As shown in Fig. 6C , doxorubicin treatment induced
apoptosis in PLC cells, and this effect was significantly potentiated
by AR down-regulation. Similar to our previous findings with TGF-h,
AR silencing potentiated the activation of caspase-3 and the up-
regulation of Bim protein levels induced by doxorubicin treatment
(Fig. 6C).
Discussion
Recent observations point to the EGFR signaling system as a
prominent player in hepatocarcinogenesis. These observations
include the overexpression and hyperactivation of the EGFR in
cirrhotic and hepatocellular carcinoma tissues and in experi-
mental models of hepatocellular carcinoma (8, 40–42). Targeting
Figure 5. A, generation of AR stable transfectants in SK-Hep1 cells. SK-Hep1 cells were stably transfected with a vector harboring murine AR cDNA and colonies
were selected as described in Materials and Methods. AR mRNA and protein were measured by multiplex RT-PCR (top ) and ELISA analysis (bottom ) of CM from
two AR-expressing clones (SK-AR1 and SK-AR2) and a control clone (cells transfected with the empty vector, SK-EV). B, effect of AR expression on the growth of
SK-Hep1 cells. The growth of SK-EV, SK-AR1, and SK-AR2 clones in complete medium was measured at different time points as described in Materials and
Methods. Growth is referred to values obtained after attachment to the plates (time, 0 hour). Points /columns, means of three experiments done in triplicates; bars, SE.
*, P < 0.05 versus control cells (SK-EV). C, anchorage-independent growth in soft agar of SK-EV, SK-AR1, and SK-AR2 cells. For each cell line, 104 cells were
resuspended in 0.2% soft agar and seeded onto 0.4% soft agar in DMEM supplemented with 10% FCS. Colonies were counted 4 weeks later after staining with crystal
violet. Points /columns, means of three experiments done in triplicates; bars, SE. D, tumorigenic potential of SK-EV, SK-AR1, and SK-AR2 cells. For each cell line,
5  106 cells were s.c. injected in the dorsal flanks of nude mice. Tumor incidence was estimated 8 weeks after injections. Tumor incidence is indicated as the number of
tumors developed with respect to the total number of injections.
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the EGFR is emerging as a novel therapeutic approach for
hepatocellular carcinoma, and encouraging experimental data
and early clinical studies have been recently published (8, 9, 39,
41, 43). Nevertheless, more advanced experiences with EGFR
inhibitors in other types of solid tumors have shown only
modest clinical responses, suggesting the need to implement
combination therapies with conventional cytostatics or with
novel targeted molecules to improve efficacy (7, 41, 44). To this
end, a profound knowledge of the biology of hepatocellular
carcinoma is essential.
In the present work, we have identified the EGFR ligand AR as a
novel growth and survival factor for hepatocellular carcinoma cells.
As we previously reported, AR gene expression is undetectable in
the healthy human liver (16); however, now, we observe that AR is
up-regulated in a significant proportion of human hepatocellular
carcinoma samples. In agreement with a recent publication (45),
we also found that ADAM17, the transmembrane metalloprotease
that cleaves the membrane-anchored AR precursor (26), was
overexpressed in hepatocellular carcinoma tissue samples. Fur-
thermore, we observed that ADAM17 mRNA levels were also up-
regulated in the cirrhotic liver when compared with healthy
controls. This finding, together with our previous observation on
the activation of AR gene expression in human liver cirrhosis (16),
suggests an enhanced availability of soluble AR from the early
stages of hepatocarcinogenesis.
We provide several lines of evidence supporting the existence
of a functional AR-mediated autocrine/paracrine loop in human
hepatocellular carcinoma cells. First, we show that treatment
with recombinant AR induced EGFR-dependent intracellular
signaling that stimulated hepatocellular carcinoma cell prolifer-
ation and resistance to TGF-h-induced apoptosis. Interestingly,
we also observed that AR was able to stimulate its own gene
expression in hepatocellular carcinoma cells through the
activation of the EGFR, suggesting the existence of a positive
feedback loop for AR production. A similar response has been
reported in other tumor cell types, such as colon cancer cells,
where AR expression is induced by the EGFR ligand TGF-a in
conjunction with the cyclooxygenase-2-derived prostaglandin E2
(29). AR was constitutively expressed and released to the CM of
hepatocellular carcinoma cells, on which it exerted promitogenic
and antiapoptotic effects through the activation of the EGFR.
Indeed, pharmacologic inhibition of AR shedding or interference
with AR binding, including the use of neutralizing antibodies,
resulted in reduced EGFR signaling and cellular proliferation.
Moreover, when hepatocellular carcinoma cells were cultured in
the absence of serum, AR protein further accumulated in the
CM, suggesting that this growth factor could be involved in the
self-sufficiency in growth signals characteristic of tumor cells,
including hepatocellular carcinoma cells (6).
To directly examine the role of AR expression in hepatocel-
lular carcinoma, we used two complementary approaches. First,
we used AR-specific siRNAs to knockdown the expression of
endogenous AR in two different human hepatocellular carcinoma
cell lines (PLC and Hep3B). Down-regulation of AR expression
resulted in substantial attenuation of basal EGFR and Erk1/2
phosphorylation, which have been found to be activated in a
significant proportion of human hepatocellular carcinomas
(3, 31). Consistent with the role of Ekr1/2 in cell proliferation,
hepatocellular carcinoma growth in serum-free media was
markedly attenuated by AR siRNAs. Nonetheless, probably the
most compelling phenotypic alteration induced by AR silencing
in hepatocellular carcinoma cells was the abrogation of
anchorage-independent growth. The ability to survive and grow
under nonadhesive conditions by inhibiting anoikis-related
apoptotic pathways is a characteristic of transformed cells that
is absent in normal epithelial cells (46). Although the
mechanisms that allow tumor cell survival under these
conditions are not completely understood, activation of the
EGFR/Erk1/2 signaling pathway has been shown to play an
essential function (36). It should be considered that the
expression of other EGFR ligands, such as TGF-a and HB-EGF,
remained unaltered upon AR silencing in hepatocellular carci-
noma cells. In light of these considerations, we could propose
that AR exerts a nonredundant role in the development of the
full neoplastic phenotype that cannot be compensated for by
other EGF family members. The reasons for this predominant
role of AR are not clear at present and deserve further studies.
However, this situation seems not to be limited only to human
hepatocellular carcinoma cells because a similar unique role for
AR in the transactivation of the EGFR in head and neck
carcinoma cells, which also express other EGFR ligands, has
been reported (23).
The ability of AR to influence hepatocellular carcinoma cell
behavior was further shown in SK-Hep1 cells, the only hepatocel-
lular carcinoma cell line tested that did not express AR but did
express TGF-a and HB-EGF (data not shown). We established two
SK-Hep1 cell lines that constitutively expressed and secreted AR
and tested their growth and tumorigenic potential. By this
approach, we could confirm that AR expression enhances key
phenotypic characteristics of hepatocellular carcinoma cancer
cells. The growth rate and colony-forming ability in semisolid agar
medium were significantly increased in AR-producing cells, as well
as the incidence of tumor development when s.c. injected in nude
mice. These observations further support a prominent role of AR in
the determination of hepatocellular carcinoma aggressive behavior.
Our findings on the modulation exerted by AR on the
response of hepatocellular carcinoma cells to TGF-h can be of
particular relevance regarding the biology of liver tumor cells.
TGF-h is not expressed in normal hepatocytes and, when
exposed to this cytokine normal liver cells, undergo growth
arrest and apoptosis (5). Conversely, TGF-h is expressed in
hepatocellular carcinoma cells; however, transformed cells have
developed resistance towards TGF-h-induced cell death, and this
trait is regarded as one important determinant in the malignant
transformation of the liver (32). Moreover, resistance to TGF-h-
induced apoptosis is intimately linked to the acquisition of self-
sustained migratory and matrix-invasive phenotypes. This is a
complex process known as epithelial-to-mesenchymal transition
and is also promoted by TGF-h during liver tumor progression
(32). In other cancers, such as colon and pancreatic cancers,
resistance to TGF-h has been attributed to defects in the
components of the TGF-h signaling pathway. However, such
mutations seem to be rare in hepatocellular carcinoma,
indicating that other pathways may be responsible for TGF-h
resistance (47). Our present observations suggest that AR
expression may play a role in the protection of hepatocellular
carcinoma cells against TGF-h-mediated apoptosis. From a
mechanistic point of view, AR down-regulation resulted in
enhanced activation of the stress-activated protein kinase JNK,
which has been involved in triggering hepatocellular carcinoma
cell apoptosis (48). Concomitantly, AR silencing resulted in
reduced Erk1/2 phosphorylation. As mentioned before, the
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EGFR/Erk1/2 pathway is crucial in preventing anoikis (36) and
has been recently identified as a key pathway in the protection
from TGF-h-induced apoptosis in late-stage liver tumorigenesis
(49). Interestingly, both protein kinases (JNK and Erk1/2) play
opposing roles in the regulation of the expression and activity of
the proapoptotic BH3-only protein Bim (33, 35–38). Consistent
with this, we observed a potent induction in Bim expression
upon AR silencing in hepatocellular carcinoma cells. BH3-only
proteins, such as Bim, target all prosurvival Bcl-2 family
members and prime the cell for apoptosis elicited by cytokines,
including TGF-h (33, 34), or cytotoxic drugs like doxorubicin
(33). Interestingly, AR silencing in the absence of any pro-
apoptotic stimuli also resulted in a significant degree of
apoptosis. Together, these findings fit well with the hypothesis
of intrinsic tumor suppression recently formulated by Lowe et al.
(50). According to this concept, cancer arises when the innate
molecular networks that connect proliferation and tumor
suppression (apoptosis) become uncoupled by the acquisition
of oncogenic lesions, such as those that constitutively activate
survival pathways. Consequently, targeting those survival pro-
grams in cancer cells can expose and reengage the innate
apoptotic mechanisms triggered by aberrant proliferation (50). In
our case, this could be exemplified by the strong up-regulation
of Bim expression, which is regarded as a tumor suppressor gene
(33), upon AR silencing.
In summary, we have identified AR as a novel player in
human hepatocellular carcinoma cell biology. Targeting AR
expression and/or activity may thus be useful to increase the
efficacy of chemotherapy in hepatocellular carcinoma. Moreover,
inhibiting AR activity may be necessary to overcome the
resistance to EGFR-targeted therapies in hepatocellular carcino-
ma (9), as recently suggested for patients with non–small cell
lung cancers in which AR overexpression correlated with a poor
response to gefitinib (44).
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Figure 6. A, effect of AR silencing on TGF-h-induced apoptosis in PLC cells. PLC cells were transfected with either siAR or the control siGL2. After 48 hours,
cells were treated or not with TGF-h (0.5 nmol/L) for 24 hours more, and apoptosis was measured as described in Materials and Methods. *, P < 0.05 versus siGL2;
#, P < 0.05 versus siGL2 plus TGF-h; x, P < 0.05, versus siAR. B, Western blot analyses of the active caspase-3 p17 subunit, the phosphorylation of JNK and
Erk1/2, and the expression of Bim in PLC cells upon AR silencing and TGF-h (0.5 nmol/L) treatment. PLC cells were transfected with either siGL2 or siAR; after
48 hours, cells were treated or not with TGF-h (0.5 nmol/L) for 24 or 48 hours more. Representative blots. C, effect of AR silencing on doxorubicin (DOX )–induced
apoptosis in PLC cells. Treatment with DOX (0.25 Ag/mL) was started 48 hours after transfection with either siGL2 or siAR, and apoptosis was measured 24 hours later.
At this, time the active caspase-3 p17 subunit and Bim protein levels were assessed by Western blotting (right ). Representative blots.
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